Q4 2025 Earnings Call February 18, 2026 3:30 AM ESTCompany ParticipantsGunilla Osswald - President & CEOJohanna Fälting ...

Roche has decided to stop developing satralizumab for bone health in Duchenne muscular dystrophy, the company announced.

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp ...

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

"I think what we have is a universal vaccine against diverse respiratory threats." The post Stanford’s New “Universal Vaccine ...

Organoids have transformed biomedical research by giving scientists miniature versions of human organs to study in the lab.

An “immune system reset” eliminated autoimmune, or Type 1, diabetes in mice in a study conducted at. Researchers say the strategy could also have potential for treating other autoimmune diseases and ...

NEW YORK – The European Commission on Monday approved Johnson & Johnson's subcutaneous Rybrevant (amivantamab) in two new dosing schedules as a first-line treatment for patients with advanced ...

TORONTO—AbbVie, the global pharmaceutical company behind Botox, has confirmed to Animal Justice that it’s stopped using animal-based testing for every batch of its anti-wrinkle products destined for ...